Irinotecan for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B

Lung Cancer

Volumn 48, Issue 3, 2005, Pages 423-428

  Kindler, Hedy L ^a   Herndon, James E ^b   Zhang, Chunfeng ^b   Green, Mark R ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b CALGB Statistical Center   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemotherapy; Irinotecan; Mesothelioma; Phase II trial

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; AGRANULOCYTOSIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; EPITHELIUM; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRANULOCYTE; HEMOGLOBIN DETERMINATION; HEMOGLOBINOPATHY; HISTOLOGY; HUMAN; INFECTION; LEUKOCYTE; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOPENIA; MALAISE; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERICARDIAL MESOTHELIOMA; PERITONEUM MESOTHELIOMA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; THROMBOCYTE DISORDER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DISEASE PROGRESSION; FEMALE; HEART NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 18844369319     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.12.002     Document Type: Article

References (24)

1. H.L. Kindler, and N.J. Vogelzang Mesothelioma E.E. Vokes H.M. Golomb Oncologic therapies 2nd ed. 2003 Springer-Verlag Berlin, Germany
2. H.L. Kindler Malignant pleural mesothelioma Curr Treat Options Oncol 1 2000 313 326
3. S.T. Ong, and N.J. Vogelzang Chemotherapy in malignant pleural mesothelioma: a review J Clin Oncol 14 1996 1007 1017
4. A.P. Chahinian, K. Antman, and M. Goutsou Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B J Clin Oncol 8 1993 1559 1565
5. H.L. Kindler, C. Belani, and J.E. Herndon Edatrexate (10-ethyl-deaza- aminopterin) with or without leucovorin rescue for malignant mesothelioma: sequential phase II trials by the Cancer and Leukemia Group B Cancer 86 1999 1985 1991
6. H.L. Kindler, F. Millard, and J.E. Herndon Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B Lung Cancer 31 2001 311 317
7. T. Ollikainen, A. Knuuttila, and S. Suhonen In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents Anticancer Drugs 11 2000 93 99
8. B.R. McLaren, B.W. Robinson, and R.A. Lake New chemotherapies in malignant mesothelioma: effects on cell growth and IL-6 production Ca Chemother Pharmacol 45 2000 502 508
9. Y. Shimada, M. Rothenberg, and S.G. Hilsenbeck Activity of CPT-11 (irinotecan hydrochloride) a topoisomerase I inhibitor, against human tumor colony-forming units Anticancer Drugs 5 1994 202 206
10. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
11. J.E. Herndon Jr.II, M.R. Green, and A.P. Chahinian Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 1998 723 731
12. Camptosar® Irinotecan HCL injection package insert. Kalamazoo, MI: Pharmacia & Upjohn Company; September 1998.
13. A. Knuuttila, T. Ollikainen, and M. Halme Docetaxel and Irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma: a feasibility study Anticancer Drugs 11 2000 257 261
14. Ferrari VD, Simoncini E, Marini G, et al. Gemcitabine (GEM) plus irinotecan (CPT11) in malignant mesothelioma a phase II study. Preliminary report. Proc Am Soc Clin Oncol 2002;21:234b.
15. T. Nakano, A.P. Chahinian, and M. Shinjo Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile Cancer 85 1999 2375 2384
16. D.A. Fennel, Steele JPC, and J. Shamash Phase II study of irinotecan, cisplatin, and mitomycin C (IPM) in malignant pleural mesothelioma Lung Cancer 41 Suppl. 2 2003 221
17. D.T. Le, M. Deavers, and K. Hunt Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma Cancer Investig 21 5 2003 682 689
18. Van Meerbeeck, P. Baas, and C. Debruyne A phase II study of gemcitabine in patients with malignant pleural mesothelioma Cancer 85 1999 2577 2582
19. H.G. Bischoff, C. Manegold, and M. Knopp Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma Proc Am Soc Clin Oncol 17 1998 464a
20. J.M. van Haarst, P. Baas, and C.H. Manegold Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma Br J Cancer 86 3 2002 342 345
21. A.K. Nowak, M.J. Byrne, and R. Williamson A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma Br J Cancer 87 2002 491 496
22. M.J. Byrne, J.A. Davidson, and A.W. Musk Cisplatin and gemcitabine for malignant mesothelioma: a phase II study J Clin Oncol 17 1999 25 30
23. G.V. Scagliotti, D.-M. Shin, and H.L. Kindler Phase II study of pemetrexed with and without folic acid and Vitamin B12 as front-line therapy in malignant pleural mesothelioma J Clin Oncol 21 2003 1556 1561
24. N. Vogelzang, J.J. Rusthoven, and J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644